FY2026 Earnings Forecast for Albemarle Issued By Scotiabank

Albemarle Corporation (NYSE:ALB) – Investment analysts at Scotiabank lowered their FY2026 earnings estimates for Albemarle in a research note issued on Monday, August 10th. Scotiabank analyst B. Isaacson now forecasts that the specialty chemicals company will post earnings per share of $11.54 for the year, down from their prior estimate of $14.76. Scotiabank has a “Sector Outperform” rating and a $190.00 price objective on the stock. The consensus estimate for Albemarle’s current full-year earnings is $12.59 per share. Scotiabank also issued estimates for Albemarle’s FY2027 earnings at $14.15 EPS.

Albemarle (NYSE:ALB) last posted its quarterly earnings results on Wednesday, August 5th. The specialty chemicals company reported $3.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.20 by $0.55. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.61 billion. Albemarle had a net margin of 3.09% and a return on equity of 10.96%. The company’s revenue for the quarter was up 31.1% on a year-over-year basis. During the same period last year, the firm earned $0.11 EPS.

ALB has been the topic of a number of other reports. Royal Bank Of Canada decreased their target price on Albemarle from $166.00 to $157.00 and set an “outperform” rating on the stock in a research report on Monday. Wall Street Zen downgraded Albemarle from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st. Argus boosted their price objective on shares of Albemarle from $185.00 to $230.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. HSBC increased their price objective on shares of Albemarle from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Finally, Bank of America raised their target price on shares of Albemarle from $190.00 to $225.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Fifteen analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Albemarle currently has a consensus rating of “Moderate Buy” and an average price target of $190.26.

Albemarle Stock Performance

NYSE ALB opened at $129.39 on Wednesday. The business has a 50 day moving average price of $135.95 and a 200 day moving average price of $163.43. The company has a market capitalization of $15.27 billion, a P/E ratio of 479.23 and a beta of 1.33. Albemarle has a 1-year low of $71.25 and a 1-year high of $221.00. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.09 and a quick ratio of 1.35.

Albemarle Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, September 11th will be issued a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 1.3%. This is a positive change from Albemarle’s previous quarterly dividend of $0.41. The ex-dividend date of this dividend is Friday, September 11th. Albemarle’s payout ratio is presently 607.41%.

Insider Buying and Selling at Albemarle

In other news, CEO J Kent Masters sold 16,393 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $183.72, for a total value of $3,011,721.96. Following the sale, the chief executive officer directly owned 87,519 shares in the company, valued at $16,078,990.68. This represents a 15.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.42% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Addison Advisors LLC purchased a new position in Albemarle in the 2nd quarter valued at about $28,000. BOKF NA boosted its stake in shares of Albemarle by 5,771.4% during the 3rd quarter. BOKF NA now owns 411 shares of the specialty chemicals company’s stock worth $33,000 after purchasing an additional 404 shares during the last quarter. Elyxium Wealth LLC purchased a new stake in shares of Albemarle during the fourth quarter worth about $34,000. EverSource Wealth Advisors LLC grew its holdings in shares of Albemarle by 536.7% during the second quarter. EverSource Wealth Advisors LLC now owns 573 shares of the specialty chemicals company’s stock worth $36,000 after buying an additional 483 shares in the last quarter. Finally, Torren Management LLC acquired a new position in shares of Albemarle in the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 92.87% of the company’s stock.

About Albemarle

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.